{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:59:56Z","timestamp":1790315996081,"version":"4.1.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The PACIFIC and GEMSTONE-301 trials established consolidation immunotherapy post-chemoradiotherapy for unresectable stage III NSCLC, but 22\u201330% of patients fail initial chemoradiotherapy, precluding consolidation. PACIFIC-2 and CheckMate 73L failures highlight the need for better integration. Induction chemoimmunotherapy before radiotherapy may improve downstaging and immune activation. This trial evaluates whether induction benmelstobart (PD-L1 inhibitor) plus anlotinib (TKI) and chemotherapy, followed by concurrent chemoradiotherapy and benmelstobart consolidation, improves progression-free survival over standard concurrent chemoradiotherapy plus consolidation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This prospective, randomized, controlled, multicenter phase II trial will enroll 152 patients with histologically or cytologically confirmed unresectable stage III NSCLC (per UICC\/AJCC 9th edition), without sensitizing driver mutations, and ECOG performance status 0\u20131. Randomization is centralized and stratified by PD-L1 tumor proportion score (&amp;lt;1% vs \u22651%), disease stage (IIIA vs IIIB\/IIIC), histology, and participating centre. Patients will be randomized 1:1 to either the experimental arm (Arm A): two cycles of induction benmelstobart (1200 mg, day 1, every 3 weeks) plus anlotinib (8 mg, days 1\u201314) and platinum-based doublet chemotherapy, followed by concurrent chemoradiotherapy (with benmelstobart withheld during radiotherapy) and benmelstobart consolidation for up to one year; or the control arm (Arm B): concurrent chemoradiotherapy followed by benmelstobart consolidation for up to one year. The primary endpoint is progression-free survival (PFS) measured from randomization. Radiotherapy consists of involved-field IMRT\/VMAT to a standard prescription of 60 Gy in 30 fractions, or a simultaneous integrated boost delivering 60\u201366 Gy to the planning gross tumor volume and 54 Gy to the planning target volume in 30 fractions; in the experimental arm, target volumes are based on post-induction residual disease with inclusion of all initially involved nodal stations. Consolidation benmelstobart will continue for up to one year or until disease progression\/unacceptable toxicity. The sample size provides 80% power (two-sided \u03b1 = 0.05) to detect a PFS hazard ratio of 0.55.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      , identifier NCT07643350.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1915557","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:32:00Z","timestamp":1790314320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled, multicenter phase II trial protocol (BEAM-LUNG)"],"prefix":"10.3389","volume":"17","author":[{"given":"Zewen","family":"Song","sequence":"first","affiliation":[{"name":"Department of Oncology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00630-6","article-title":"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108583","article-title":"Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT \u2192 durvalumab in Canada: The RELEVANCE study","volume":"204","author":"Wheatley-Price","year":"2025","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: The phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100808","article-title":"65O CheckMate 73L: Phase III study comparing nivolumab (N)\u00a0+\u00a0concurrent chemoradiotherapy (CCRT) followed by N\u00a0\u00b1\u00a0ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"Immuno-Oncology Technol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/jco.2025.43.16_suppl.8012","article-title":"The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist)","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1897","article-title":"Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung cancer: A phase II nonrandomized controlled trial","volume":"10","author":"Ross","year":"2024","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108883","article-title":"Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real-world multicenter retrospective study","volume":"211","author":"Li","year":"2026","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"LBA8004","DOI":"10.1200\/jco.2025.43.17_suppl.lba8004","article-title":"R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(26)00049-5","article-title":"Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial","volume":"27","author":"Zhong","year":"2026","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12967-025-06485-4","article-title":"scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer","volume":"23","author":"Huang","year":"2025","journal-title":"J Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010812","article-title":"Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC","volume":"13","author":"Tang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.020","article-title":"PL03.06 EA5181: Phase 3 trial of concurrent and consolidative durvalumab vs consolidation durva alone for unresectable stage 3 NSCLC","volume":"20","author":"Varlotto","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41392-024-02008-7","article-title":"First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic\/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1915557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:32:01Z","timestamp":1790314321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1915557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1915557"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1915557","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1915557"}}